Article info
PDFDrug information (i. anti-infectives, ii. cytostatics, iii. others)
DGI-042 Hypomagnesemia as a Possible Marker of Efficacy in Patients with Head and Neck Carcinoma in First-Line Treatment with Cetuximab
Citation
DGI-042 Hypomagnesemia as a Possible Marker of Efficacy in Patients with Head and Neck Carcinoma in First-Line Treatment with Cetuximab
Publication history
- First published March 12, 2013.
Online issue publication
October 20, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions